ReviewClinical pharmacokinetics2009
Pharmacology of morphine in obese patients: clinical implications.
Review in Clinical pharmacokinetics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Pooled it
- Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide.Clinical pharmacokinetics · 2017Trial
- Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach.Clinical pharmacokinetics · 2014Trial
- Morphine versus oxycodone analgesia after percutaneous kidney stone surgery: a randomised double blinded study.Urolithiasis · 2013Trial
- Efficacy of ultrasound-guided transversus abdominis plane block after laparoscopic bariatric surgery: a double blind, randomized, controlled study.Obesity surgery · 2013Trial
- Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients.Clinical pharmacokinetics · 2011Trial
- Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.European journal of clinical pharmacology · 2011Trial
- Safety and efficacy of remifentanil in patients undergoing bariatric and metabolic surgeries - A systematic review.Indian journal of anaesthesia · 2025Article
- Article
- The association of obesity with post-cesarean inpatient opioid consumption.International journal of obesity (2005) · 2024Article
- Obesity and anesthetic pharmacology: simulation of target-controlled infusion models of propofol and remifentanil.Korean journal of anesthesiology · 2021Article
- Perioperative Inpatient Opioid Consumption Following Autologous Free-Flap Breast Reconstruction Patients: An Examination of Risk and Patient-Reported Outcomes.Annals of surgical oncology · 2021Article
- Effects of Obstructive Sleep Apnea and Obesity on Morphine Pharmacokinetics in Children.Anesthesia and analgesia · 2020Article
- Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen.Clinical pharmacokinetics · 2016Observational
- Bariatric Surgery Patients' Response to a Chronic Pain Rehabilitation Program.Obesity surgery · 2015Article
- A Review of the Toxicologic Implications of Obesity.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2015Review
- Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability.Pharmacology & therapeutics · 2015Review
- Challenges in the optimisation of post-operative pain management with opioids in obese patients: a literature review.Obesity surgery · 2013Review
- Pilot study examining the frequency of several gene polymorphisms involved in morphine pharmacodynamics and pharmacokinetics in a morbidly obese population.Obesity surgery · 2011Article
- Drug metabolism alterations in nonalcoholic fatty liver disease.Drug metabolism reviews · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Morphine is an analgesic drug used to treat acute and chronic pain. Obesity is frequently associated with pain of various origins (e.g. arthritis, fibromyalgia, cancer), which increases the need for analgesic drugs. Obesity changes drug pharmacokinetics, and for certain drugs, specific modalities of prescription have been proposed for obese patients. However, scant data are available regarding the pharmacokinetics and pharmacodynamics of morphine in obesity. Prescription of morphine depends on pain relief but the occurrence of respiratory adverse effects correlates with obesity, and is not currently taken into account. Variations in the volume of distribution, elimination half-life and oral clearance of morphine, as well as recent advances in the respective roles of drug-metabolizing enzymes, catechol-O-methyltransferase and the mu opioid receptor in morphine pharmacokinetics and pharmacodynamics, may contribute to differences between obese and non-obese patients. In addition, drug-drug interactions may alter the disposition of morphine and its glucuronide metabolites, which may either increase the risk of adverse effects or reduce drug efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.